Prevalence of trachoma in four marakez of Elmenia and Bani Suef Governorates, Egypt

Khaled Amer, Andreas Müller, Hussein Mohamed Abdelhafiz, Tawfik Al-Khatib, Ana Bakhtiari, Sophie Boisson, Gamal Ezz El Arab, Hema Gad, Bruce A. Gordon, Ahmad Madian, Ahmed Tarek Mahanna, Samir Mokhtar, Omar H. Safa, Mohamed Samy, Mohammad Shalaby, Ziad Atta Taha, Rebecca Willis, Ashraf Yacoub, Abdul Rahman Mamdouh, Ahmed Kamal Younis, Mohamed Bahaa Eldin Zoheir, Paul Courtright, Anthony W. Solomon & for the Global Trachoma Mapping Project

To cite this article: Khaled Amer, Andreas Müller, Hussein Mohamed Abdelhafiz, Tawfik Al-Khatib, Ana Bakhtiari, Sophie Boisson, Gamal Ezz El Arab, Hema Gad, Bruce A. Gordon, Ahmad Madian, Ahmed Tarek Mahanna, Samir Mokhtar, Omar H. Safa, Mohamed Samy, Mohammad Shalaby, Ziad Atta Taha, Rebecca Willis, Ashraf Yacoub, Abdul Rahman Mamdouh, Ahmed Kamal Younis, Mohamed Bahaa Eldin Zoheir, Paul Courtright, Anthony W. Solomon & for the Global Trachoma Mapping Project (2018) Prevalence of trachoma in four marakez of Elmenia and Bani Suef Governorates, Egypt, Ophthalmic Epidemiology, 25:sup1, 70-78, DOI: 10.1080/09286586.2018.1446536

To link to this article: https://doi.org/10.1080/09286586.2018.1446536
Prevalence of trachoma in four marakez of Elmenia and Bani Suef Governorates, Egypt

Khaled Amer, Andreas Müller, Hussein Mohamed Abdelhafiz, Tawfik Al-Khatib, Ana Bakhtiar, Sophie Boisson, Gamal Ezz El Arab, Hema Gad, Bruce A. Gordon, Ahmad Tarek Mahanna, Samir Mokhtar, Omar H. Safa, Mohamed Samy, Mohammad Shalaby, Ziad Atta Taha, Rebecca Willis, Ashraf Yacoub, Abdul Rahman Mamdouh, Ahmed Kamal Younis, Mohamed Bahaa Eldin Zoheir, Paul Courtright, and Anthony W. Solomon

*Ministry of Health and Population, Cairo, Egypt; †Centre for Eye Research, University of Melbourne, Melbourne, Australia; ‡Ministry of Health, Sana’a, Yemen; †Task Force for Global Health, Decatur, GA, USA; †Department of Public Health, the Environment and Social Determinants of Health, World Health Organization, Geneva, Switzerland; †Magrabi Foundation, Cairo, Egypt; ‡Health Office, Deir Mawass, Egypt; †Eye Health Office, Elmenia, Egypt; Health Office, Abu Quorquas, Egypt; †Eye Health Office, Bani Suef, Egypt; †Health Office, Matai, Egypt; †‡Health Office, Elfasn, Egypt; †Killimanjaro Centre for Community Ophthalmology, Division of Ophthalmology, University of Cape Town, Cape Town, South Africa; †Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK; †Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland

ABSTRACT

Purpose: In 2015, to determine where interventions are needed to eliminate trachoma as a public health problem from Egypt, we initiated population-based prevalence surveys using the Global Trachoma Mapping Project platform in four suspected-endemic marakez (districts; singular: markaz) of the governorates of Elmenia and Bani Suef.

Methods: In each markaz, 30 households were selected in each of 25 villages. Certified graders examined a total of 3682 children aged 1–9 years in 2993 households, noting the presence or absence of trachomatous inflammation—follicular (TF) and trachomatous inflammation—intense (TI) in each eye. A total of 5582 adults aged ≥15 years living in the same households were examined for trachomatous trichiasis (TT). Household-level access to water and sanitation was recorded.

Results: Three of four marakez had age-adjusted TF prevalence estimates in 1–9-year-olds of >10%; the other markaz had a TF prevalence estimate of 5–9.9%. Estimates of the age- and gender-adjusted prevalence of unmanaged TT in adults ranged from 0.7% to 2.3%. Household-level access to water and sanitation was high. (We did not, however, measure use of water or sanitation facilities.)

Conclusions: Each of the four marakez surveyed has trachoma as a public health problem, with a need for implementation of the SAFE (surgery, antibiotics, facial cleanliness, environmental improvement) strategy. Further mapping is also required to determine the need for interventions in other areas of Egypt.

BACKGROUND

With an estimated 89 million residents, Egypt is the most populous country in the Middle East. However, it fares better than some of its neighbours on a variety of health indicators (including deaths from malaria, maternal and infant mortality rates, and prevalence of HIV); neglected tropical diseases such as schistosomiasis, soil-transmitted helminths, and trachoma are endemic.2,3

Trachoma’s presence in Egypt was documented in the Ebers medical papyrus dating from 1500 BC.4 During the Napoleonic wars in the early 1800s, troops deployed to Egypt were heavily affected.5 At the beginning of the twentieth century, in some areas, nearly all young children developed active disease, and more than two-thirds of adults were observed to have trichiasis.6,7 From 1903 to 1923, seminal work on trachoma was undertaken in Egypt by Arthur Ferguson MacCallan.8 In the 1970s and 1980s, it was still a widespread problem, including in the capital, Cairo.9,10 In the mid-1980s, hyperendemic trachoma was seen in two rural communities of Beheira Governorate in the Nile Delta: active trachoma was present in 59% of 3-year olds, while trichiasis and/or...
entropion were seen in children as young as 9 years old and affected a staggering 75% of adult females.\textsuperscript{11,12}

In 1999, a population-based survey in the Nile Delta Governorate of Elmenofiya found that 37% of 2–6-year-olds had active trachoma, while 6.5% of adults had trichiasis.\textsuperscript{13} A 2002 population-based survey of Elmenia Governorate estimated the prevalence of active trachoma in 2–10-year-olds to be 42%, and the prevalence of trichiasis in ≥50-year-olds to be 6.2%.\textsuperscript{14} In 2003, trachoma rapid assessments (TRAs)\textsuperscript{15} were undertaken in 15 villages of Elfayoum Governorate. The village-level proportions of 2–10-year-old children observed to have active trachoma ranged from 16% to 85%.\textsuperscript{16} A further series of modified TRAs was undertaken in 2010–2011 in 78 villages of four governorates; the proportions of villages in which ≥10% of children examined had the active trachoma sign trachomatous inflammation— follicular (TF)\textsuperscript{17} were 6/20 in Elfayoum, 18/20 in Elmenia, 19/20 in Elmenofiya, and 16/18 in Kafr Elsheikh.\textsuperscript{18}

Transmission of trachoma’s causative agent, \textit{Chlamydia trachomatis},\textsuperscript{19} is thought to be facilitated by a combination of factors including poor sanitation,\textsuperscript{11,20} inadequate access to water for face-washing,\textsuperscript{21,22} and overcrowding.\textsuperscript{23,24} Despite economic improvements across Egypt and the introduction of sewerage to many areas of the Nile Delta in recent decades, trachoma is thought to remain a threat to public health in parts of the country. We sought to collect contemporary data necessary for planning interventions against this disease: specifically, population-based prevalence estimates of TF, trachomatous trichiasis (TT) and access to water and sanitation.\textsuperscript{25,26}

\textbf{Methods}

\textbf{Ethical considerations}

Ethics approval was received from the Research Ethics Committee of the London School of Hygiene & Tropical Medicine (reference numbers 6319 and 8355) and the Egypt National Ministry of Health Ethics Committee (20 May 2013). Verbal informed consent was obtained from all adults examined and from the household head on behalf of children in their care.

\textbf{Study design}

We used the principles and protocols of the Global Trachoma Mapping Project (GTMP).\textsuperscript{27,28} The survey sample size in each evaluation unit was based on an expected TF prevalence of 10% and a desire to be 95% confident of estimating the true TF prevalence with absolute precision of 3%. The design effect was estimated at 2.65, leading to our sample size estimate of 1019 1–9-year-olds, which was then inflated by 20% to account for partial non-response.\textsuperscript{27} We did not calculate a specific sample size for TT, for which prevalences are generally very low, but instead used a household-sampling approach in which a fixed number of households were selected in each cluster, with that number determined by the number of children that we needed to include to generate an adequate sample size for TF.\textsuperscript{27}

We undertook population-based surveys in the Governorates of Elmenia and Bani Suef, using the markaz (district; plural: marakez) as the evaluation unit. Due to constraints in availability of personnel, only four surveys could be conducted. Elmenia Governorate was believed (on the basis of recent research\textsuperscript{29}) to have a high TT burden; its most northern, most southern, and a central markaz were selected for inclusion. Bani Suef Governorate lies just to the north of Elmenia Governorate. Its most southern markaz was surveyed, based on the understanding that local conditions here were most similar to those in Elmenia. Within each markaz, clusters were selected by creating a list of villages with corresponding village-level population estimates, then systematically sampling from that list with probability proportional to population size.\textsuperscript{26} In order to select sufficient households in which 1019 × 1.2 = 1222 one-to-nine-year olds would be resident, 25 villages were selected in each markaz, and 30 households were chosen in each selected village. A compact segment sampling technique was employed to select households.\textsuperscript{30–35}

\textbf{Fieldwork}

Trachoma grading was undertaken according to the WHO simplified grading scheme,\textsuperscript{17} using 2.5× binocular loupes (OptiVISOR, Donegan Optical, Lenexa, KS, USA) and sunlight illumination. Graders and data recorders were trained prior to the surveys and certified according to the standardized training protocols of the GTMP, as described elsewhere.\textsuperscript{27} Version 3 of the training system was used.\textsuperscript{36}

All consenting residents in the household aged ≥1 year were examined for trichiasis, TF, and trachomatous inflammation—intense (TI). Eyes with trichiasis were considered to have TT if they also had TS, or if the eyelid could not be everted for conjunctival examination by the grader. Participants identified to have trichiasis were asked whether they had been offered surgery or epilation by a health professional. All children identified as having active trachoma (TF and/or TI in one or both eyes) were provided with two tubes of
1% tetracycline eye ointment and their parents or guardian were instructed on how to use it. Participants with trichiasis were referred for surgery.

**Data recording and analysis**

Data entry and upload was accomplished via the bespoke Open Data Kit-based GTMP data capture system running on Android smartphones. Data were encrypted during transit and stored in a secure server with only the study investigators having access; cleaning was undertaken by the GTMP data managers (AB and RW). TF data were adjusted at cluster level for the age of those examined, in 1-year age bands. TT data were adjusted at cluster level for age and gender of those examined, in 5-year age bands. Markaz-level estimates were generated by taking the arithmetic mean of the adjusted cluster-level proportions. Confidence intervals for TF and TT prevalence estimates were determined by bootstrapping the adjusted cluster-level proportions of each sign, with replacement, over 10,000 replicates.

**Results**

Surveys were conducted from 29 November to 25 December 2015 in Abu Quorquas, Deir Mawass and Matai markaz of Elmenia Governorate, and Elfashn markaz of Bani Suef Governorate. Field teams visited a total of 2993 households in 100 clusters across the four markaz. In total, of 3708 1–9-year-old children resident in selected households, 3682 were examined (Table 1).

The estimated age-adjusted markaz-level TF prevalence in 1–9-year olds ranged from 8.4% to 25.3% across the four markaz (Table 2, Figure 1). A total of 134 individuals aged ≥15 years had TT, of whom 46 had bilateral TT. The estimated age- and gender-adjusted prevalence of TT exceeded 1% in each of the four markaz (Table 2, Figure 2). In Elfashn, 14 (64%) of the 22 individuals identified as having TT had been offered surgery or epilation by the health system; corresponding proportions elsewhere were 8/26 (31%, Matai), 17/59 (29%, Deir Mawass), and 7/27 (26%, Abu Quorquas).

Based on these prevalence estimates for TF and TT, applied to 2017 population estimates, for trachoma elimination purposes, >1.7 million people in the four markaz should receive antibiotics, facial cleanliness promotion, and environmental improvement and 8712 people require eyelid surgery to correct TT (Table 3).

**Discussion**

In the absence of an effective vaccine, the public health approach to preventing trachoma blindness involves reducing *C. trachomatis* transmission intensity by maximising access to water and sanitation and encouraging personal hygiene; periodically clearing prevalent infection with antibiotics; and preventing further trachoma-related vision loss in those who already have trichiasis through provision of quality eyelid surgery. These interventions together

| Table 1. Adults and children resident, examined, absent and refused, by markaz, Global Trachoma Mapping Project, Egypt, 2015. |
|---|---|---|---|---|---|
| Markaz | Enumerated | Examined | Absent | Refused | Enumerated | Examined | Absent | Refused |
|---|---|---|---|---|---|---|---|---|---|
| Abu Quorquas | 925 | 916 (99.0) | 6 (0.6) | 3 (0.3) | 1502 | 1479 (98.5) | 16 (1.1) | 6 (0.4) |
| Deir Mawass | 1098 | 1097 (99.9) | 1 (0.1) | 0 (0.0) | 1458 | 1400 (96.0) | 54 (3.7) | 4 (0.3) |
| Matai | 842 | 837 (99.4) | 4 (0.5) | 1 (0.1) | 1513 | 1480 (97.8) | 14 (0.9) | 19 (1.3) |
| Elfashn | 843 | 832 (98.7) | 11 (1.3) | 0 (0.0) | 1556 | 1223 (78.6) | 299 (19.2) | 33 (2.1) |
| Total | 3708 | 3682 (99.3) | 22 (0.6) | 4 (0.1) | 6029 | 5582 (92.6) | 383 (6.4) | 62 (1.0) |

| Table 2. Prevalence of trachomatous inflammation—follicular (TF) and trachomatous inflammation—intense (TI) in 1–9-year olds, and prevalence of trachomatous trichiasis (TT) in ≥15-year olds, four markaz of Elmenia and Bani Suef Governorates, Global Trachoma Mapping Project, Egypt, 2015. |
|---|---|---|---|---|---|
| Markaz | Age-adjusted\(^a\) prevalence of TF in 1–9-year olds (95% CI) | Age-adjusted\(^a\) prevalence of TI in 1–9-year olds (95% CI) | Age- and gender-adjusted\(^b\) prevalence of TT in ≥15-year olds (95% CI) | Age- and gender-adjusted\(^b\) prevalence of unmanaged TT in ≥15-year olds (95% CI) |
|---|---|---|---|---|
| Abu Quorquas | 12.0 (7.5–18.2) | 3.5 (1.8–5.5) | 1.1 (0.5–1.9) | 0.8 (0.4–1.5) |
| Deir Mawass | 25.3 (19.2–32.6) | 7.0 (3.8–10.7) | 3.1 (1.9–4.6) | 2.3 (1.2–3.6) |
| Matai | 8.4 (5.6–10.7) | 0.9 (0.2–1.6) | 1.2 (0.5–1.9) | 0.9 (0.4–1.4) |
| Elfashn | 11.6 (7.3–17.3) | 8.0 (4.6–11.8) | 1.1 (0.5–1.9) | 0.7 (0.2–1.5) |

\(^a\)Adjusted for age in 1-year age bands (see text).
\(^b\)Adjusted for gender and age in 5-year age bands (see text).

CI: Confidence interval.
comprise the “SAFE strategy”: surgery, antibiotics, facial cleanliness, environmental improvement. The SAFE strategy works and is recommended by the World Health Organization, which leads an Alliance aiming to eliminate trachoma as a public health problem by 2020. SAFE strategy interventions, however, have to compete for prioritization in a crowded public health landscape. Robust prevalence data are required to make the case for funding. Though there are some limitations of our work here—particularly the relatively large size of evaluation units surveyed—we believe that our estimates are of evidence-based metrics, are reproducible, and justify planning for SAFE strategy implementation in the areas surveyed.

In three of four suspected trachoma-endemic mara-kez of Egypt, we found the TF prevalence to be ≥10%. In Matai, the fourth markaz, TF prevalence was 8.5%. Based on WHO guidelines, Abu Quorquas, Deir Mawass, and Elfashn should be managed with three annual rounds of antibiotic mass drug administration (MDA) plus initiatives to ensure facial cleanliness and improve the environment, before a repeat prevalence survey 6–12 months after the third MDA round. In Matai, one round of MDA, facial cleanliness, and environmental improvement activities are needed before re-survey. In

![Figure 1. Prevalence of trachomatous inflammation—follicular (TF) in 1–9-year olds, four marakez of Elmenia and Bani Suef Governorates, Global Trachoma Mapping Project, Egypt, 2015.](image-url)
each round, antibiotic coverage of at least 80% of the markaz population is recommended. 46,47 Although WHO guidelines recommend that the A, F, and E components of the SAFE strategy be implemented wherever the TF prevalence exceeds the 5% elimination threshold, it is notable that access to water and sanitation
in these four marakez was nearly universal. In each marakaz, >95% of households had an improved water source in the residence or yard, and all households visited had access to an improved latrine (Table 4). These levels of access exceed by some margin the access thresholds expected to confer herd protection against trachoma—a demonstration of the heterogeneity of environmental correlates of trachoma and the fact that access to sanitation hardware does not necessarily lead to protection from diseases associated with its absence: access may still be inadequate for some population subsets, or facilities may not be used in ways that decrease the risk of C. trachomatis transmission. Anecdotally at least, in areas of Egypt in which mains sewerage is not available, people often defecate where their animals are kept, rather than in household latrines.

The prevalence of unmanaged TT ranged from 0.7% (Elfashn) to 2.3% (Deir Mawass) in the four marakez surveyed here. Elimination of trachoma as a public health problem requires that the prevalence of TT unknown to the health system be reduced to <0.2% in adults. Community-based case identification and provision of quality lid surgery by certified operators is urgently needed in these populations to stem the tide of trachoma-related blindness and visual impairment.

These findings indicate the urgent need to implement the SAFE strategy for trachoma elimination in all four marakez. F and E interventions should incorporate established techniques for achieving sustained behaviour change. Priority should be given to Deir Mawass, where prevalences of both TF and TT were the highest of the four marakez, and the proportion of people with TT who had previously been offered management was the lowest. In all, however, >1.7 million people in these four marakez need services to eliminate trachoma as a public health problem—and it is likely that other marakaz in Egypt will also need interventions, a hypothesis that will need to be confirmed or refuted through further population-based surveys. It is currently estimated that at least 29 marakez still need to undergo baseline surveys. Of Egypt’s international neighbours, only Sudan is currently thought to have a public health problem from trachoma, so cross-border issues are not currently believed to be a priority here.

Global progress towards the target of eliminating trachoma as a public health problem has recently gathered pace, with a number of countries now validated by the World Health Organization as having achieved that milestone at national level. Armed with the evidence generated by this series of surveys and those that will follow, Egypt can now proceed to trachoma action planning and engage with relevant stakeholders, starting along the path to national trachoma elimination.

### Acknowledgments

The Global Trachoma Mapping Project was supported by a grant from the United Kingdom’s Department for International Development (DFID; ARIES: 203145) to Sightsavers, which led a consortium of non-governmental organizations and academic institutions to support health ministries to complete baseline trachoma mapping worldwide; and the United States Agency for International Development (USAID), through the ENVISION project implemented by RTI International under cooperative agreement number AID-OAA-A-11-00048, and the END in Asia project implemented by FHI360 under cooperative agreement number OAA-A-10-00051. A committee established in March 2012 to examine issues surrounding completion of global trachoma mapping was initially funded by a grant from Pfizer to the International Trachoma Initiative. AWS was a Wellcome Trust Intermediate Clinical Fellow (098521) at the London School of Hygiene & Tropical Medicine and is now, like SB and BAG, a member of staff at the World Health Organization. The authors alone are responsible for the views expressed in this article, which do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated. None of the funders had any role in project design, in project implementation or analysis or interpretation of data, in the decisions on where, how or when to publish in the peer reviewed press, or in preparation of the manuscript.

### References

1. United Nations Statistics Division. *Population and Vital Statistics Report. Statistical Papers, Series A Vol. LXIX: Data Available as of 1 January 2017*. New York: United Nations; 2017
2. Hotez PJ, Kasem M. Egypt: its artists, intellectuals, and neglected tropical diseases. *PLoS Negl Trop Dis*. 2016;10:e0005072. doi:10.1371/journal.pntd.0005072.

3. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. *PLoS Negl Trop Dis*. 2012;6:e1475. doi:10.1371/journal.pntd.0001475.

4. Bryan CP. *The Papyrus Ebers: Translated from the German Version*. London: Bles; 1930

5. Taylor HR. *Trachoma: A Blinding Scourge from the Bronze Age to the Twenty-First Century*. East Melbourne: Centre for Eye Research Australia; 2008

6. Wilson RP. Ophthalmic survey in village in Bahtim. *Ann Rep Giza Mem Ophthalmol Lab*. 1929;4:72–86.

7. Attiah MAH, El Togby AF. Factors influencing the course of trachoma. *Bull Ophthalmol Soc Egypt*. 1937;30:137–142.

8. MacCallan M, Arthur Ferguson MacCallan CBE, MD, FRCS (1872-1955), trachoma pioneer and the ophthalmic campaign in Egypt 1903-1923. *J Med Biogr*. 2018;26(1):59–67. doi:10.1177/0967772016643540.

9. Said ME, Goldstein H, Korra A, El-Kashlan K. Prevalence and causes of blindness in urban and rural areas of Egypt. *Public Health Rep*. 1970;85:587–599. doi:10.2307/4593913.

10. International Eye Foundation. *Findings from the South Cairo Eye Disease Survey: Integrated Urban Primary Eye Care Program*. Bethesda, MD: International Eye Foundation; 1985

11. Courtright P, Sheppard J, Schachter J, Said ME, Dawson CR. Trachoma and blindness in the Nile Delta: current patterns and projections for the future in the rural Egyptian population. *Br J Ophthalmol*. 1989;73:536–540. doi:10.1136/bjo.73.7.536.

12. Courtright P, Sheppard J, Lane S, Sadek A, Schachter J, Dawson CR. Latrine ownership as a protective factor in inflammatory trachoma in Egypt. *Br J Ophthalmol*. 1991;75:322–325. doi:10.1136/bjo.75.6.322.

13. Ezz Al Arab G, Tawfik N, El Gendy R, Anwar W, Courtright P. The burden of trachoma in the rural Nile Delta of Egypt: a survey of menofiga governorate. *Br J Ophthalmol*. 2001;85:1406–1410. doi:10.1136/bjo.85.12.1406.

14. Elarab GE, Khan M. Estimation of the prevalence of trachoma in Egypt. *Br J Ophthalmol*. 2010;94:392. doi:10.1136/bjo.2009.165795.

15. Negrel AD, Taylor HR, West S. *Guidelines for Rapid Assessment for Blinding Trachoma* (WHO/PBD/GET/00.8). Geneva: World Health Organization; 2001

16. Ezz Al Arab G. *Trachoma Rapid Assessment and Planning for Intervention: A Pilot Study in Fayoum Governorate*. Research Brief No. 9. Cairo: Partnership in Development Research, American University in Cairo; 2003

17. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. *Bull World Health Organ*. 1987;65:477–483.

18. National Task Force of Trachoma. *Rapid Assessment of Active Trachoma in Egypt*. Cairo: Ministry of Health and Population; 2011

19. Hadfield J, Harris SR, Seth-Smith HMB, et al. Comprehensive global genome dynamics of Chlamydia trachomatis show ancient diversification followed by contemporary mixing and recent lineage expansion. *Genome Res*. 2017;27:1220–1229. doi:10.1101/gr.212647.116.

20. Garn JV, Boisson S, Willis R, et al. Sanitation and water supply coverage thresholds associated with active trachoma: modeling cross-sectional data from 13 countries. *PLoS Negl Trop Dis*. 2018;12:e0006110. doi:10.1371/journal.pntd.0006110.

21. Bailey R, Downes B, Downes R, Mabey D. Trachoma and water use; a case control study in a Gambian village. *Trans R Soc Trop Med Hyg*. 1991;85:824–828. doi:10.1111/j.1365-3156.1991.tb04070.x.

22. West S, Munoz B, Lynch M, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. *Lancet*. 1995;345:155–158. doi:10.1016/S0140-6736(95)90167-1.

23. Elshafie BE, Osman KH, Macleod C, et al. The epidemiology of trachoma in Darfur States and Khartoum State, Sudan: results of 32 population-based prevalence surveys. *Ophthalmic Epidemiol*. 2016;23:381–391. doi:10.1080/09286586.2016.1243718.

24. Taleo F, Macleod CK, Marks M, et al. Integrated mapping of Yaws and Trachoma in the Five Northern-Most Provinces of Vanuatu. *PLoS Negl Trop Dis*. 2017;11:e0005267. doi:10.1371/journal.pntd.0005267.

25. Smith JL, Haddad D, Polack S, et al. Mapping the global distribution of trachoma: why an updated atlas is needed. *PLoS Negl Trop Dis*. 2011;5:e973. doi:10.1371/journal.pntd.0000973.

26. Solomon AW, Zondervan M, Kuper H, Buchan JC, Mabey DCW, Foster A. *Trachoma Control: A Guide for Programme Managers*. Geneva: World Health Organization; 2006

27. Solomon AW, Pavluck A, Courtright P, et al. The Global Trachoma mapping project: methodology of a 34-country population-based study. *Ophthalmic Epidemiol*. 2015;22:214–225. doi:10.3109/09286586.2015.1037401.

28. Solomon AW, Kurylo E. The global trachoma mapping project. *Community Eye Health*. 2014;27:18.

29. Mousa A, Courtright P, Kazanjian A, Bassett K. A community-based eye care intervention in Southern Egypt: impact on trachomatous trichiasis surgical coverage. *Middle East Afr J Ophthalmol*. 2015;22:478–483. doi:10.4103/0974-9233.167808.

30. Abashaw A, Macleod C, Riang J, et al. Prevalence of Trachoma in Gambella Region, Ethiopia: results of three population-based prevalence surveys conducted with the global trachoma mapping project. *Ophthalmic Epidemiol*. 2016;23:77–83. doi:10.1080/09286586.2016.1247875.

31. Adamu Y, Macleod C, Adamu L, et al. Prevalence of trachoma in Benishangul Gumuz Region, Ethiopia: results of seven population-based surveys from the global trachoma mapping project. *Ophthalmic Epidemiol*. 2016;23:70–76. doi:10.1080/09286586.2016.1247877.

32. Adera TH, Macleod C, Endriyas M, et al. Prevalence of and risk factors for trachoma in Southern Nations, Nationalities, and Peoples’ Region, Ethiopia: results of 40 population-based prevalence surveys carried out with the global trachoma mapping project.
33. Bero B, Macleod C, Alemayehu W, et al. Prevalence of and risk factors for trachoma in oromo regional state of Ethiopia: results of 79 population-based prevalence surveys conducted with the global trachoma mapping project. *Ophthalmic Epidemiol*. 2016;23:392–405. doi:10.1080/09286586.2016.1243717.

34. Shereif ST, Macleod C, Gigar G, et al. The prevalence of trachoma in Tigray Region, Northern Ethiopia: results of 11 population-based prevalence surveys completed as part of the global trachoma mapping project. *Ophthalmic Epidemiol*. 2016;23:94–99. doi:10.1080/09286586.2016.1250917.

35. Phiri I, Manangazira P, Macleod CK, et al. The burden of and risk factors for trachoma in selected districts of Zimbabwe: results of 16 population-based prevalence surveys. *Ophthalmic Epidemiol*. 2018;25(sup 1):181–191. doi:10.1080/09286586.2017.1298823.

36. Courtright P, Gass K, Lewallen S, et al. Global Trachoma Mapping Project: Training for Mapping of Trachoma (Version 3). Available at: http://www.trachomacoalition.org/node/122. London: International Coalition for Trachoma Control; 2014.

37. Solomon AW, Mabey DC. Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomatis. *Vaccine*. 2005;23:5281–5282. doi:10.1016/j.vaccine.2005.05.042.

38. Rabiü M, Alhassan MB, Ejere HO, Evans JR. Environmental sanitary interventions for preventing active trachoma. *Cochrane Database Syst Rev*. 2012; CD004003. doi: 10.1002/14651858.CD004003.pub4.

39. Ejere HO, Alhassan MB, Rabiü M. Face washing promotion for preventing active trachoma. *Cochrane Database Syst Rev*. 2015;2:CD003659.

40. Boisson S, Engels D, Gordon BA, et al. Water, sanitation and hygiene for accelerating and sustaining progress on neglected tropical diseases: a new global strategy 2015–20. *Int Health*. 2016;8(Suppl 1):i19–i21. doi:10.1093/inthealth/ihw073.

41. Evans JR, Solomon AW. Antibiotics for trachoma. *Cochrane Database Syst Rev*. 2011;3:CD001860.

42. Burton M, Habtamu E, Ho D, Gower EW. Interventions for trachoma trichiasis. *Cochrane Database Syst Rev*. 2015;1:CD004008.

43. Francis V, Turner V. Achieving Community Support for Trachoma Control (WHO/PBL/93.36). Geneva: World Health Organization; 1993.

44. Ngondi J, Onsario A, Matthews F, et al. Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: A cross-sectional study. *Lancet*. 2006;368:589–595. doi:10.1016/S0140-6736(06)69202-7.

45. Hammou J, El Ajaroumi H, Hasbi H,AN, Hmadna A, El Maaroufi A. In Morocco, the elimination of trachoma as a public health problem becomes a reality. *Lancet Glob Health*. 2017;5:e250–e1. doi:10.1016/S2214-109X(17)30023-2.

46. Harding-Esch EM, Sillah A, Edwards T, et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET trial in the Gambia. *PLoS Negl Trop Dis*. 2013;7:e2115. doi:10.1371/journal.pntd.0002115.

47. West SK, Bailey R, Munoz B, et al. A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. *PLoS Negl Trop Dis*. 2013;7:e2415. doi:10.1371/journal.pntd.0002415.

48. Oswald WE, Stewart AE, Kramer MR, et al. Active trachoma and community use of sanitation, Ethiopia. *Bull. World Health Organ*. 2017;95:250–260. doi:10.2421/BLT.16.177758.

49. Freeman MC, Garn JV, Sclar GD, et al. The impact of sanitation on infectious disease and nutritional status: a systematic review and meta-analysis. *Int J Hyg Environ Health*. 2017. doi:10.1016/j.ijheh.2017.05.007.

50. World Health Organization. *Validation of Elimination of Trachoma as a Public Health Problem (WHO/HTM/NTD/2016.8)*. Geneva: World Health Organization; 2016.

51. Merbs S, Resnikoff S, Kello AB, Mariotti S, Greene G, West SK. *Trichiasis Surgery for Trachoma*. 2nd. Geneva: World Health Organization; 2015.

52. Delea MG, Solomon H, Solomon AW, Freeman MC. Interventions to maximize facial cleanliness and achieve environmental improvement for trachoma elimination: A review of the grey literature. *PLoS Negl Trop Dis*. 2018;12:e0006178. doi:10.1371/journal.pntd.0006178.

53. Mpyet C, Kello AB, Solomon AW. Global elimination of trachoma by 2050: a work in progress. *Ophthalmic Epidemiol*. 2015;22:148–150. doi:10.3109/09286586.2015.1045987.

54. Hassan A, Ngondi JM, King JD, et al. The prevalence of blinding trachoma in northern states of Sudan. *PLoS Negl Trop Dis*. 2011;5:e1027. doi:10.1371/journal.pntd.0001027.

55. World Health Organization. WHO alliance for the global elimination of trachoma by 2020: progress report on elimination of trachoma, 2014–2016. *Wkly Epidemiol Rec*. 2017; 92: 359–368.

56. International Coalition for Trachoma Control. *Trachoma Action Planning*. London: International Coalition for Trachoma Control; 2015.

**Appendix**

The Global Trachoma Mapping Project Investigators are: Agatha Aboe (1,11), Liknaw Adamu (4), Wondo Alemayehu (4,5), Membere Alemu (4), Neal D. E. Alexander (9), Ana Bakhtiari (2,9), Berhanu Bero (4), Sarah Bovill (8), Simon J. Brooker (1,6), Simon Bush (7,8), Brian K. Chu (2,9), Ana Bakhtiari (2,9), Berhanu Bero (4), Sarah Bovill (8), Simon J. Brooker (1,6), Simon Bush (7,8), Brian K. Chu (2,9), Anna Massey (8), Els Mathieu (6,11), Siobhain McCullagh (8), Addis Mekasha (4), Tom
Millar (4,8), Caleb Mpyet (3,5), Beatriz Muñoz (6,9), Jeremiah Ngondi (1,3,6,11), Stephanie Ogden (6), Alex Pavluck (2,4,10), Joseph Pearce (10), Serge Resnikoff (1), Virginia Sarah (4), Boubacar Sarr (5), Alemayehu Sisay (4), Jennifer L. Smith (11), Anthony W. Solomon (1,2,3,4,5,6,7,8,9,10,11), Jo Thomson (4); Sheila K. West (1,10,11), Rebecca Willis (2,9).

Key: (1) Advisory Committee, (2) Information Technology, Geographical Information Systems, and Data Processing, (3) Epidemiological Support, (4) Ethiopia Pilot Team, (5) Master Grader Trainers, (6) Methodologies Working Group, (7) Prioritisation Working Group, (8) Proposal Development, Finances and Logistics, (9) Statistics and Data Analysis, (10) Tools Working Group, (11) Training Working Group.